Pelthos Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | ||
| Net product revenues | $16,206 | $— |
| License and collaboration revenues | 589 | — |
| Total revenue | 16,795 | — |
| Operating expenses | ||
| Cost of goods sold | 3,988 | — |
| Selling, general and administrative | 42,453 | 6,392 |
| Research and development | 1,228 | 1,179 |
| Amortization of intangible assets | 1,556 | — |
| Total operating expenses | 49,225 | 7,571 |
| Operating loss | (32,430) | (7,571) |
| Other (expense) income | ||
| Interest expense | (3,012) | (786) |
| Impairment of intangible assets | (285) | — |
| Change in fair value of convertible debt | (14,984) | — |
| Interest income and other income | 5 | 402 |
| Total other (expense) income | (18,276) | (384) |
| Net loss before provision for income taxes | (50,706) | (7,955) |
| Provision for income taxes | (7,387) | — |
| Net loss and comprehensive loss | $(43,319) | $(7,955) |
| Net loss per common share - basic and diluted | $(23.04) | $(14.27) |
| Weighted average number of common shares outstanding during the period - basic and diluted | 1,880,498 | 557,447 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.